Page 2 - Treating Fields News Today

Novocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the FDA. The PMA application for LUNAR was submitted with a filing date of December 15, 2023, and is now under substantive review by the FDA. Novocure expects to receive a

Lung cancer — it can literally take your breath away. Despite chemo, radiation, and immunotherapy, it is still one of the hardest cancers to treat.

Novocure today announced that research on Tumor Treating Fields therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma and...

Now, doctors are battling lung cancer in medical settings and taking the fight to the patient's home.

ROOT, Switzerland, October 15, 2023--Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of patient-reported health-related global and functional quality of life scores from the randomized phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC).

Novocure today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 ? 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis...

Novocure today announced its participation in the upcoming American Society for Radiation Oncology 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical,...

Novocure (NASDAQ:NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical,

ROOT, Switzerland, September 29, 2023--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target tumor during treatment.

1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with an HR of 0.74. This effect was more pronounced in treatment with immune checkpoint inhibitors. 2. Most frequent TTFields therapy-related adverse events were grade 1 to 2 skin related events Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic